1.	Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: CSET 1542-JANORL2, 2009-017047-34, NCT01211938
2.	Phase III Randomized Study of Imatinib Mesylate Alone or With Interferon alfa or Low-Dose Cytarabine Versus Interferon alfa Standard Therapy Followed By Allogeneic Stem Cell Transplantation in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: III-MK-CML-IV, EU-20248, NCT00055874
3.	Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: GCO 09-1300-00002, P01CA108671, MPD-RC 112, NCT01259856
4.	A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: daliah2011, NCT01387763
5.	Treatment of Acute Leukemia Relapse After Allotransplantation Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 18 to 90 Sponsor: Other Protocol IDs: Allo-Relapse-2011, NCT01369368
6.	Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage III-IV Head and Neck Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02009, A091101, U10CA031946, N01CM62201, NCT01711541
7.	Phase II Randomized Study of Hydroxyurea With Versus Without Imatinib Mesylate in Patients With Recurrent or Progressive Meningiomas. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: SRSI-GICNO-08-002, GICNO 08-002, NOVARTIS-SRSI-GICNO-08-002, NCT00904735